Results 171 to 180 of about 17,843,832 (369)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

open access: yesMolecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit   +19 more
wiley   +1 more source

Economic Clubs and European Commitment. Evidence from the International Business Cycles [PDF]

open access: yes
This paper examines the emergence of economic clubs and its coherence with the european commitments. to this end, it analyses business cycle comovements in six industrialised economies, which are pooled into several clusters.
Bovi, M.
core  

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

open access: yesMolecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson   +11 more
wiley   +1 more source

Openness, Globalization and Economic Growth: Empirical Evidence from Cote d´Ivoire, 1969-2002 [PDF]

open access: yes
The purpose of this paper is to examine the relationships between openness, globalization on economic growth in Côte d’Ivoire which adopted the openness of its economy as the basic way for development at the beginning of its economic history in 1960 ...
Aka, B.F.
core  

REVIEWS [PDF]

open access: yesThe Mariner's Mirror, 1957
JOHN MUNDAY   +24 more
openaire   +2 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy